SEC Comment Letter 0000000000-24-013345 to bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc.
Date: Dec. 4, 2024 · CIK: 0001712762 · Accession: 0000000000-24-013345
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283521
Letter
December 4, 2024 Maria Zannes Chief Executive Officer bioAffinity Technologies, Inc. 3300 Nacogdoches Road, Suite 216 San Antonio, Texas 78217 Re:bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed November 27, 2024 File No. 333-283521 Dear Maria Zannes: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jane Park at 202-551-7439 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc:Leslie Marlow, Esq.
Show Raw Text
December 4, 2024
Maria Zannes
Chief Executive Officer
bioAffinity Technologies, Inc.
3300 Nacogdoches Road, Suite 216
San Antonio, Texas 78217
Re:bioAffinity Technologies, Inc.
Registration Statement on Form S-1
Filed November 27, 2024
File No. 333-283521
Dear Maria Zannes:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jane Park at 202-551-7439 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:Leslie Marlow, Esq.